Reslizumab for pediatric eosinophilic esophagitis

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 461-465

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cinquil ; eosinophils; IL 5; pediatric eosinophilic esophagitis; reslizumab

Indexed keywords

ALLERGEN; CHEMOKINE RECEPTOR CCR3; CINQUIL; CORTICOSTEROID; CYTOKINE; EOTAXIN; EOTAXIN 3; EP 00763592; EP 00765392; INTERLEUKIN 5; OVALBUMIN; RESLIZUMAB; UNCLASSIFIED DRUG; US 06316227; US 06734286; WO 09201472; WO 09535375;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ASTHMA; BIOASSAY; BONE MARROW CELL; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIET RESTRICTION; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; EOSINOPHIL; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GASTROENTERITIS; FOOD ALLERGY; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; LOEFFLER PNEUMONIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL CHEMOTAXIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SCHOOL CHILD; SENSITIZATION; SINGLE DRUG DOSE; TH2 CELL; TISSUE DISTRIBUTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; EOSINOPHILIA; ESOPHAGITIS; HUMANS; PATENTS AS TOPIC; PEDIATRICS; RATS;

EID: 77955003518     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.41     Document Type: Review

References (37)

1. Assaad A: Eosinophilic esophagitis: association with allergic disorders. Gastrointest. Endosc. Clin. N. Am. 18, 119-132 (2008).
2. Roy-Ghanta S, Larosa DF, Katzka DA: Atopic characteristics of adult patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 6, 531-535 (2008).
3. Plaza-Martin AM, Jimenez-Feijoo R, Andaluz C et al.: Polysensitization to aeroallergens and food in eosinophilic esophagitis in a pediatric population. Allergolog. Immunopathol. 35, 35-37 (2007).
4. Sugnanam KK, Collins JT, Smith PK et al.: Dichotomy of food and inhalant allergen sensitization in eosinophilic esophagitis. Allergy 62, 1257-1260 (2007).
5. De Angelis P, Morino G, Pane A et al.: Eosinophilic esophagitis: management and pharmacotherapy. Exp. Opin. Pharmacother. 9, 731-740 (2008).
6. Blanchard C, Wang N, Stringer KF et al.: Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest. 116, 536-547 (2006).
7. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU: Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J. Allergy Clin. Immunol. 108, 954-961 (2001).
8. Mishra A, Rothenberg ME: Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 125, 1419-1427 (2003).
9. Mishra A, Hogan SP, Brandt EB, Rothenberg ME: An etiological role for aeroallergens and eosinophils in experimental esophagitis. J. Clin. Invest. 107, 83-90 (2001).
10. Blanchard C, Rothenberg ME: Basic pathogenesis of eosinophilic esophagitis Gastrointest. Endosoc. Clin. N. Am. 18, 133-143 (2008).
11. Oh HE, Chetty R: Eosinophilic gastroenteritis. J. Gastroenterol. 43, 741-750 (2008).
12. Liacouras CA: Pharmacologic treatment of eosinophilic esophagitis. Gastrointest. Endosc. Clin. N. Am. 18, 169-178 (2008).
13. Walsh GM: Advances in the immunobiology of eosinophils and their role in disease. Crit. Rev. Clin. Lab. Sci. 36 5 453-496 (1999).
14. Blanchard C, Rothenberg ME: Biology of the eosinophil. Adv. Immunol. 101, 81-121 (2009).
15. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183, 195-201 (1996).
16. Iwamoto T, Takatsu K: Evaluation of airway hyperreactivity in interleukin-5 transgenic mice. Int. Arch. Allergy Immunol. 1(Suppl.), 28-30 (1995).
17. Kay AB, Klion AD: Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol. Allergy Clin. North Am. 24, 645-666 (2004).
18. Bullock JZ, Villanueva JM, Blanchard C et al.: Interplay of adaptative Th2 immunity with eotaxin-3 C-C chemokine receptor 3 in eosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 45, 22-31 (2007).
19. Blanchard C, Wang N, Stringer KF et al.: Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest. 116, 536-547 (2006).
20. Liu LY, Sedgwick JB, Bates ME et al.: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor a in the airway after allergen challenge. J. Immunol. 169, 6452-6458 (2002).
21. Liu LY, Sedgwick JB, Bates ME et al.: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J. Immunol. 169, 6459-6466 (2002).
22. Gevaert P, Bachert C, Holtappels G et al.: Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. J. Allergy 58, 371-379 (2003).
23. Egan RW, Athwal D, Bodmer MW et al.: Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 49(9), 779-790 (1999).
24. Egan RW, Athwahl D, Chou C-C et al.: Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int. Arch. Allergy Immunol. 107, 321-322 (1995).
25. Cook WJ, Walter LJ, Murgolo NJ et al.: Structure and humanization of a rat monoclonal Fab to human interleukin-5. Protein Eng. 9, 623-628 (1996).
26. Walsh GM: Mepolizumab and eosinophil-mediated disease. Curr. Med. Chem. 16, 4774-4778 (2009).
27. Kips JC, OConnor BJ, Langley SJ et al.: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Resp. Crit. Care Med. 167, 1655-1659 (2003).
28. Walsh GM: Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr. Opin. Mol. Ther. 11(3), 329-336 (2009).
29. Prussin C, James SP, Huber MM, Klion AD, Metcalfe DD: Pilot study of anti-IL-5 in eosinophilic gastroenteritis. J. Allergy Clin. Immunol. 111(Suppl. 2), S275 (2003).
30. Straumann A, Conus S, Grzonka P et al.: Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59(1), 21-30 (2010).
31. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ: Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J. Exp. Med. 182(4), 1169-1174 (1995)
32. Gevaert P, Lang-Loidolt D, Lackner A et al.: Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 118, 1133-1141 (2006).
33. Kim YJ, Prussin C, Martin B et al.: Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J. Allergy Clin. Immunol. 114, 1449-1455 (2004).
34. Nair P, Pizzichini MM, Kjarsgaard M et al.: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985-993 (2009).
35. Haldar P, Brightling CE, Hargadon B et al.: Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973-984 (2009).
36. NCT00587288: Efficacy and safety of reslizumab to treat poorly controlled asthma Ception Therapeutics Inc. (2009) www.clinicaltrials.gov
37. Ception Therapeutics initiates Phase II/III clinical trial for its lead product reslizumab in eosinophilic esophagitis (EE) in children. Ception Therapeutics Inc. Press release, 5 March 2008 www.medicalnewstoday.com/ articles/171907.php